BC Innovations | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Interleukin-25 (IL-25; IL-17E)

Infectious disease INDICATION: Clostridium Patient sample and mouse studies suggest IL-25 could help treat Clostridium difficile infection (CDI). In patient intestinal tissue samples, levels of IL-25 protein were lower than in samples from healthy volunteers....
BC Innovations | May 12, 2016
Distillery Therapeutics

Therapeutics: Thymic stromal lymphopoietin (TSLP); interleukin-33 (IL-33; NF-HEV); IL-25 (IL-17E)

Inflammation INDICATION: Inflammation; liver fibrosis; pulmonary fibrosis Mouse studies suggest combined inhibition of IL-33, TSLP and IL-25 could help treat cytokine-driven inflammation and fibrosis. In a mouse model of Schistosomiasis mansoni infection, systemic knockout of...
BC Innovations | Feb 6, 2014
Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis IL-25 (IL-17E) Patient sample and mouse studies suggest inhibiting IL-25 could help treat pulmonary fibrosis. In a mouse model of Schistosoma mansoni...
BC Week In Review | Dec 3, 2012
Company News

Lorus, Cancer Research U.K. deal

Cancer Research U.K.'s Drug Development Office ( DDO ) and commercial subsidiary Cancer Research Technology (CRT) Ltd. agreed to a clinical development partnership with Lorus to develop the biotech's proinflammatory cytokine interleukin-17E (IL-17E) cancer compound. Under the...
BC Week In Review | May 7, 2012
Company News

Lorus, Roche deal

Lorus received worldwide rights to patents owned by Roche's Genentech Inc. unit covering Lorus' IL-25 (IL-17E). Lorus has patents pending for the use of IL-17E in an undisclosed number of countries to treat cancer. Lorus...
BioCentury | Apr 9, 2012
Strategy

Divvying up skill sets

AstraZeneca plc 's deal for five clinical mAbs from Amgen Inc. 's inflammation and pulmonary portfolio puts the pharma close to its goal of getting 40% of its pipeline from external sources. For Amgen, last...
BC Innovations | Nov 17, 2011
Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation IL-17; IL-17 receptor (IL17R; IL17RA); IL-25 (IL-17E) Cell culture and mouse studies suggest that a cell-permeable decoy peptide that binds...
BC Innovations | May 5, 2011
Targets & Mechanisms

Breast cancer therapy with IL-25

A team of U.S. and Taiwan researchers has shown that IL-25, a proinflammatory cytokine involved in allergic inflammation, also exerts potent cytotoxic effects in breast cancer cells and decreases mammary tumor growth in mice. 1...
BC Innovations | Apr 21, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer IL-25 (IL-17E); IL-17 receptor B (IL-17RB; IL-25R) In vitro and mouse studies suggest that IL-25 or its mimetics could help treat breast cancer....
BC Innovations | Sep 9, 2010
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Inflammation Inflammatory disease IL-25 In vitro studies suggest that blocking IL-25 may help treat Churg-Strauss syndrome (CSS), which is characterized by systemic vasculitis and eosinophilia....
Items per page:
1 - 10 of 16